Worldwide Large Molecule Bioanalytical Testing Services Industry to 2029 - Increased Complication of Product Designs and Engineering is Driving Growth - ResearchAndMarkets.com

07 Dec 2022
www.businesswire.com
DUBLIN--(BUSINESS WIRE)--The "Large Molecule Bioanalytical Testing Services Market Analysis by Phase, by Type, by Test Type, by Therapeutic Area, by End user by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
'Large Molecule Bioanalytical Testing Services Market Analysis by Phase, by Type, by Test Type, by Therapeutic Area, by End user by Region - Global Forecast to 2029'
The large molecule bioanalytical testing services market size is estimated to be USD 1.7 billion in 2021 and is expected to witness a CAGR of 11.58%% during the forecast period 2022-2029.
The market is expected to grow due to , and rising demands for advanced and high-quality large molecule bioanalytical testing services.
Other factors driving market expansion include increased regulatory supervision and a significant risk of product failure. However, concerns about legality while outsourcing is expected to limit the market growth.
Companies Mentioned
Charles River (US)
Medpace (US)
WuXi AppTec (China)
Eurofins Scientific (Luxembourg)
SGS SA (Switzerland)
PRA Health Sciences (US)
Syneos Health (US)
ICON plc (Ireland)
PPD Inc. (US)
Celerion (US)
This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including phase, type, test type, therapeutic area, and end user from 2021 to 2029.
Segmentation: Large Molecule Bioanalytical Testing Services Market Report 2021-2029
By Phase (Revenue, USD Billion)
Clinical
By Type (Revenue, USD Billion)
ADA
Others
By Test Type (Revenue, USD Billion)
Bio availability
PD
PK
Other Tests
By Therapeutic Area (Revenue, USD Billion)
Oncology
Neurology
Cardiology
Others
By End user (Revenue, USD Billion)
Large Firms
SMEs
By Region (Revenue, USD Billion)
North America
U.S
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of Europe
China
Japan
India
Australia
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
GCC
Rest of MEA
For more information about this report visit https://www.researchandmarkets.com/r/qcwwb8
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.